Pembrolizumab
Pembrolizumab (formerly lambrolizumab, brand name Keytruda) is a humanized antibody used in cancer immunotherapy. This includes treating melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, and stomach cancer. It is given by slow injection into a vein.
anti-PD-1 drug (monoclonal antibody to PD-1 programmed cell death receptor): pembrolizumab (Keytruda) approved for advanced or unresectable melanoma not responding to other drugs 1).
Pembrolizumab for non-Small-cell lung cancer
Pembrolizumab for glioblastoma
References
1)
U.S. Food and Drug Administration (FDA). FDA approves Keytruda for advanced melanoma. 2014. https://wayback.archive-it.org/7993/ 20170112023823/http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/ ucm412802.htm